text stringlengths 1 711 |
|---|
0.6% |
0.0% |
0.5% |
1.0% |
1.5% |
2.0% |
2.5% |
3.0% |
3.5% |
4.0% |
4.5% |
5.0% |
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 |
Vicks Halls Mucinex Ricola |
Strepsils Sudafed Robitussin Benylin |
Source: Euromonitor, J.P. Morgan |
As per NielsenIQ, KVUE lost -133 bps of value share in the four-week period ending |
5/6/23, sequentially worse from losing -113 bps as of PYE while gaining +159 bps as of |
PY. As it relates to volume share, the company seems to have improved YTD, |
although it lost -3 bps in the four-week period ending 5/6/23 vs. -13 bps PYE but |
slightly gained +6 bps as of PY. Below we show how both value and volume share |
performed for the 4, 13, and 52 weeks ending 5/6/23 for KVUE and some of its |
competitors. |
Figure 102: Cough & Cold - U.S. Value Share |
For Periods Ending 5/06/23, YOY (bps) |
(133) |
(230) |
(156) (148) |
(940) |
(94) (93) |
(6) |
782 |
184 |
419 |
12 36 |
198 |
32 |
813 |
343 |
539 |
401 |
14 |
278 |
(1,200) |
(1,000) |
(800) |
(600) |
(400) |
(200) |
- |
200 |
400 |
600 |
800 |
1,000 |
KENVUE PROCTER & |
GAMBLE |
BAYER AG RECKITT PRIVATE |
LABEL |
CHURCH & |
DWIGHT |
HALEON |
4W 13W 52W |
Source: NielsenIQ, J.P. Morgan |
Figure 103: Cough & Cold - U.S. Volume Share |
For Periods Ending 5/06/23, YOY (bps) |
(3) |
8 |
(2) |
(0) |
(22) |
(1) (3) |
(0) |
28 |
5 |
9 |
6 |
1 2 |
(1) |
25 |
7 |
9 |
17 |
0 |
3 |
(30) |
(20) |
(10) |
- |
10 |
20 |
30 |
40 |
KENVUE PROCTER & |
GAMBLE |
BAYER AG RECKITT PRIVATE |
LABEL |
CHURCH & |
DWIGHT |
HALEON |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.